These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 23506904)
21. In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation. Bi YA; Kimoto E; Sevidal S; Jones HM; Barton HA; Kempshall S; Whalen KM; Zhang H; Ji C; Fenner KS; El-Kattan AF; Lai Y Drug Metab Dispos; 2012 Jun; 40(6):1085-92. PubMed ID: 22381335 [TBL] [Abstract][Full Text] [Related]
22. Effects of Drug Transporters on Pharmacological Responses and Safety. Liu CX; Yi XL; Fan HR; Wu WD; Zhang X; Xiao XF; He X Curr Drug Metab; 2015; 16(9):732-52. PubMed ID: 26630905 [TBL] [Abstract][Full Text] [Related]
23. Drug-drug interactions related to altered absorption and plasma protein binding: theoretical and regulatory considerations, and an industry perspective. Hochman J; Tang C; Prueksaritanont T J Pharm Sci; 2015 Mar; 104(3):916-29. PubMed ID: 25557998 [TBL] [Abstract][Full Text] [Related]
24. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Zamek-Gliszczynski MJ; Lee CA; Poirier A; Bentz J; Chu X; Ellens H; Ishikawa T; Jamei M; Kalvass JC; Nagar S; Pang KS; Korzekwa K; Swaan PW; Taub ME; Zhao P; Galetin A; Clin Pharmacol Ther; 2013 Jul; 94(1):64-79. PubMed ID: 23588311 [TBL] [Abstract][Full Text] [Related]
25. Dealing with the complex drug-drug interactions: towards mechanistic models. Varma MV; Pang KS; Isoherranen N; Zhao P Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151 [TBL] [Abstract][Full Text] [Related]
26. Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications. Saito H Pharmacol Ther; 2010 Jan; 125(1):79-91. PubMed ID: 19837111 [TBL] [Abstract][Full Text] [Related]
27. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Harwood MD; Neuhoff S; Carlson GL; Warhurst G; Rostami-Hodjegan A Biopharm Drug Dispos; 2013 Jan; 34(1):2-28. PubMed ID: 22927116 [TBL] [Abstract][Full Text] [Related]
28. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Shou M Curr Opin Drug Discov Devel; 2005 Jan; 8(1):66-77. PubMed ID: 15679174 [TBL] [Abstract][Full Text] [Related]
29. Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. Alim K; Bruyère A; Lescoat A; Jouan E; Lecureur V; Le Vée M; Fardel O Expert Opin Drug Metab Toxicol; 2021 Mar; 17(3):259-271. PubMed ID: 33292029 [No Abstract] [Full Text] [Related]
30. Environmental chemicals as substrates, inhibitors or inducers of drug transporters: implication for toxicokinetics, toxicity and pharmacokinetics. Fardel O; Kolasa E; Le Vee M Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):29-46. PubMed ID: 22176607 [TBL] [Abstract][Full Text] [Related]
31. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014. Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199 [TBL] [Abstract][Full Text] [Related]
32. Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions. Maeda K Drug Metab Pharmacokinet; 2020 Feb; 35(1):76-88. PubMed ID: 31948854 [TBL] [Abstract][Full Text] [Related]
34. Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters. Ramboer E; Vanhaecke T; Rogiers V; Vinken M Drug Metab Rev; 2013 May; 45(2):196-217. PubMed ID: 23368091 [TBL] [Abstract][Full Text] [Related]
35. A regulatory viewpoint on transporter-based drug interactions. Zhang L; Zhang YD; Strong JM; Reynolds KS; Huang SM Xenobiotica; 2008 Jul; 38(7-8):709-24. PubMed ID: 18668428 [TBL] [Abstract][Full Text] [Related]
37. Are circulating metabolites important in pharmacokinetic drug-drug interactions? A retroanalysis of clinical data. Zhao YS; Chen F; Li L Curr Drug Metab; 2014; 15(8):767-90. PubMed ID: 25705906 [TBL] [Abstract][Full Text] [Related]
38. Principles and experimental considerations for in vitro transporter interaction assays. Bhoopathy S; Bode C; Naageshwaran V; Weiskircher-Hildebrandt EA; Hidalgo IJ Methods Mol Biol; 2014; 1113():229-52. PubMed ID: 24523116 [TBL] [Abstract][Full Text] [Related]
39. Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in-vitro kinetic parameters for the prediction of clinically relevant drug-drug interactions. Grandvuinet AS; Vestergaard HT; Rapin N; Steffansen B J Pharm Pharmacol; 2012 Nov; 64(11):1523-48. PubMed ID: 23058041 [TBL] [Abstract][Full Text] [Related]
40. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances. Obach RS Curr Opin Drug Discov Devel; 2009 Jan; 12(1):81-9. PubMed ID: 19152216 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]